Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Procoxacin bidirectionally inhibits osteoblastic and osteoclastic activity in bone and suppresses bone metastasis of prostate cancer

Fig. 6

14–3-3ζ is identified as a drug target of Pro. A Predicted 3D structure of Pro binding to 14–3-3ζ. B Western blot of 14–3-3ζ in primary cell lysate and samples separated by amino magnetic microbeads (A Beads, positive control), empty magnetic microbeads (E beads, negative control) and Pro-conjugated magnetic microbeads (P Beads). C Overlay plot of sensorgrams of the Pro/14–3-3ζ binding in SPR. D Fit curve of dose-dependent saturation binding of Pro to 14–3-3ζ with dissociation constant (KD) indicated. E Knockdown of 14–3-3ζ in C4-2B with three shRNAs. F Viability of shCtrl- or sh140-transfected C4-2B cells treated with Pro. The IC50 values were given in parentheses. G Relative luciferin luminescence intensity (RLI) in MC3T3-ORE cells under indicated conditions. H Representative bioluminescence images of mice bearing C4-2B-shCtrl or C4-2B-sh140 cells treated with PBS or Pro (n=6). Bioluminescence was quantified on the right. *P < 0.05, ***P < 0.001, ns, no significance

Back to article page